QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Pomdoctor Limited (POM)

Healthcare

No action
Fundamental
1
Sentiment
1
Technical
2

Do Nothing: fundamentalScore 1 and qualitativeScore 1 are both below the required floor of 3 (shadow admission unavailable - qualitativeScore 1 never takes the shadow branch), and the overnight-gap gate also fires at a 37.3% max gap (> 5%); no entry qualifies in either class - the pullback limit is countertrend under the SMA200 clause (price 2.03 < sma200 3.24 with sma50 < sma200 and no momentum reclaim) and the breakout buy-stop above the settled high 2.73 carries R/R 0.58 (< 1.0).

Analysis as of 2026-10-22· more than 2 trading days ago

Company overview

Pomdoctor Limited operates an e-commerce platform for direct pharmaceutical sales to consumers and is developing an online healthcare services platform for managing chronic illnesses in China. The company connects patients with medical professionals and medications, utilizing a virtual hospital model and a comprehensive pharmaceutical supply chain. Founded in 2010, it is headquartered in Guangzhou, China.

Fundamental

very weak
Fundamental1
Speculative fundamentals

Pomdoctor's fundamentals are speculative with going-concern issues and negative cash flow, indicating high investment risk.

Pomdoctor (POM) is a small Chinese online-pharmacy ADR whose auditor and management both flag substantial doubt about its ability to continue as a going concern. Cash of RMB12.6M covers roughly 6% of current liabilities, shareholders' equity is negative, every year since 2021 has been loss-making, and operating cash flow was negative by RMB148.5M in FY2025. Both discounted-cash-flow models return negative value per share. Growth decelerated to +6% in H1 2026 with gross margin compressing, while a securities class action, a Nasdaq bid-price deficiency and unremediated material weaknesses add risk. Fundamentals read as speculative and high-risk; not investment-worthy.

Sentiment

very weak
Sentiment1
Bearish sentiment

Sentiment is bearish due to ongoing Nasdaq delisting risks and a lack of positive catalysts.

The dominant driver is a Nasdaq Staff Delisting Determination (announced, 2026-10-09, bearish) compounded by the ADR-program termination, 10-for-1 share consolidation and direct Class A listing (announced, 2026-10-19, bearish); the 14-day scoring window reads bearish at polarity_score ≈ -0.31 across 7 scored items, while the 30–90-day baseline yielded only one unique on-topic scored item and therefore supports no measurable delta, so the sentiment delta is indeterminate. The Red-Flag Screen is not clean — explicit going-concern doubt from the FY2025 auditor and management and repeated in the H1 2026 interim, corroborated by in-window coverage — so a severe red-flag cap applies.

Technical

weak
Technical2
High volatility

The stock exhibits high volatility and a downward trend, with recent price spikes followed by rapid declines.

Chart quality 2/5 (bounce-only): a one-day 3x spike (2026-10-21 regular-session close 2.00 off a 0.69 low, 48.8M shares) was fully faded the next session (-32.6% to 2.03 on 14.3M shares), leaving price below the EMA9 (2.34), EMA21 (2.29), SMA20 (2.67) and a declining SMA200 (3.24) with only the consolidation-distorted SMA50 (1.67) beneath. MACD histogram is negative (-0.10) with the line (0.13) under its signal (0.24), RSI14 48.07 and Williams %R -52.31 are neutral, ADX14 35.02 describes the strength of a down-sloping move rather than a bullish trend, and ATR14 at 0.71 (35.0% of price) makes any structure-based stop a gap-risk proposition. This is a spike-and-fade tape, not a low-risk long base. The entry is blocked regardless by fundamentalScore 1 and qualitativeScore 1 (both below the required floor of 3) and by a 37.3% maximum overnight gap (> 5%).

You’re looking at 2026-10-22 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.